Gila Lustig
Overview
Explore the profile of Gila Lustig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
PLOS Glob Public Health
. 2024 Apr;
4(4):e0002703.
PMID: 38603677
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of...
2.
Karim F, Riou C, Bernstein M, Jule Z, Lustig G, van Graan S, et al.
Nat Commun
. 2024 Mar;
15(1):2360.
PMID: 38491050
SARS-CoV-2 clearance requires adaptive immunity but the contribution of neutralizing antibodies and T cells in different immune states is unclear. Here we ask which adaptive immune responses associate with clearance...
3.
Lustig G, Ganga Y, Rodel H, Tegally H, Khairallah A, Jackson L, et al.
Virus Evol
. 2024 Feb;
10(1):vead075.
PMID: 38361824
One mechanism of variant formation may be evolution during long-term infection in immunosuppressed people. To understand the viral phenotypes evolved during such infection, we tested SARS-CoV-2 viruses evolved from an...
4.
Khan K, Lustig G, Romer C, Reedoy K, Jule Z, Karim F, et al.
Nat Commun
. 2023 Dec;
14(1):8078.
PMID: 38057313
Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating variants by over 30 mutations in the spike protein alone. Here we report on the isolation of the...
5.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
medRxiv
. 2023 Dec;
PMID: 38045321
Background: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose...
6.
Samsunder N, Lustig G, Ngubane S, Maseko T, Rambaran S, Ngcapu S, et al.
Diagn Progn Res
. 2023 Jul;
7(1):14.
PMID: 37491317
Background: Rapid antigen tests detecting SARS-CoV-2 were shown to be a useful tool in managing the COVID-19 pandemic. Here, we report on the results of a prospective diagnostic accuracy study...
7.
Samsunder N, Lustig G, De Vos M, Ngcapu S, Giandhari J, Tshiabuila D, et al.
J Clin Virol
. 2023 Jun;
165:105498.
PMID: 37329842
Background: Concerns around accuracy and performance of rapid antigen tests continue to be raised with the emergence of new SARS-CoV-2 variants. Objective: To evaluate the performance of two widely used...
8.
Lustig G, Ganga Y, Rodel H, Tegally H, Jackson L, Cele S, et al.
medRxiv
. 2022 Dec;
PMID: 36451879
The milder clinical manifestations of Omicron infection relative to pre-Omicron SARS CoV-2 raises the possibility that extensive evolution results in reduced pathogenicity. To test this hypothesis, we quantified induction of...
9.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al.
Nat Commun
. 2022 Oct;
13(1):6057.
PMID: 36229444
No abstract available.
10.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al.
Nat Commun
. 2022 Aug;
13(1):4686.
PMID: 35948557
SARS-CoV-2 Omicron (B.1.1.529) BA.4 and BA.5 sub-lineages, first detected in South Africa, have changes relative to Omicron BA.1 including substitutions in the spike receptor binding domain. Here we isolated live...